Rashid Gabbasov

Rashid Gabbasov has been working in the field of pre-clinical drug research since 2010. Rashid began their career as an Undergraduate Researcher at Kazan State Medical University in 2010. Rashid then went on to pursue a Graduate Student role at Kazan Federal University in 2011. In the same year, they took on a Postdoctoral Associate role at Fox Chase Cancer Center, where they gained 2+ years of experience in pre-clinical assessment of molecular mechanisms of single and combined drug action. Rashid'scurrent project focuses on pre-clinical evaluation of combination of PARP and HSP90 inhibitors in order to improve outcomes of BRCA mutation-negative ovarian cancer patients. Rashid also has extensive experience with patient-derived xenografts, handling the full pipeline of establishing PDXs from processing and implantation of patient tumors into mice, to isolation of patient tumor-derived cell lines and recruiting them in pre-clinical drug research. In 2019, they joined Carisma Therapeutics as a Senior Scientist, and has since held Scientist II and Scientist roles.

Rashid Gabbasov completed a Doctor of Philosophy - PhD in Biochemistry from Kazan Federal University in 2016, after completing a BS/MS combined degree program in Genetics from the same university in 2011.